| Today’s Big NewsAug 17, 2023 |
| By James Waldron Abcuro will draw on an oversubscribed series B round to continue the journey of its anti-KLRG1 candidate through clinical trials for a muscle disease and cancers. |
|
|
|
| Philadelphia, PA |  |
|
|
By James Waldron Three months after laying off a quarter of its workforce, Selecta Biosciences is now halting investment in all but one of its non-partnered programs to eke out enough cash into 2027. |
By Max Bayer The last clinical update from Celixir came more than three years ago just as the COVID-19 pandemic was upending ongoing trials. Now, a newly-formed SPAC has plucked the company out of the biotech graveyard. |
By Gabrielle Masson Global life science investor Novo Holdings is backing research product provider Sangon Biotech in a $290 million financing that will help the China-based company diversify its portfolio and expand internationally. |
By Helen Floersh Progress in regenerative medicine has been hampered in part by the fact that while the resulting induced pluripotent stem cells, or iPS cells, are very similar to natural stem cells, their genomes still carry the biological “memories” of the cells from which they were derived. Now, researchers have found a way to make that transformation more thorough. |
By Joseph Keenan Parexel, a global CRO, will collaborate with digital pharma platform provider Partex to leverage AI to further biotech's drug discovery and development as well as streamline clinical trials. |
By Kevin Dunleavy After traveling a long road full of potholes, Ipsen has finally reached its destination, gaining FDA approval for Sohonos to treat ultra-rare bone disease fibrodysplasia ossificans progressive. Ipsen called the “de-risked” when it acquired Clementia Pharmaceuticals for $1 billion back in 2019. |
By Andrea Park After getting wind of a new approach to treating overactive bladder—several years after it earned CE mark clearance in Europe—the FDA has granted the technology de novo clearance in the U.S. |
By Angus Liu Pfizer is shelling out $43 billion to acquire Seagen primarily for the Seattle biotech’s antibody-drug conjugate capabilities. But a trial win for a small-molecule cancer drug makes the deal more attractive. |
By Paige Minemyer Cigna has launched a new tool that will allow its members to use their smartphones to check for dental health issues including gum disease and cavities. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we discuss left-handedness and its significance in neurodevelopmental and psychiatric disorder research. |
|
|---|
|
|
|
October 16-17 | Boston, MA Examine the ways the IRA has impacted the drug pricing and access landscape and review business implications for affordability and evaluate strategies for engaging with stakeholders. Secure your spot today and save $400 on registration. Savings end August 21st! 
|
|
Whitepaper Learn how process liquids and buffers impact your total cost of ownership (TCO) and how outsourcing can revolutionize your approach, ensuring quality standards and improving productivity. Thermo Fisher Scientific Process Liquid Preparation Services |
Whitepaper In oncology, traditional methods for determining sales force size & structure are no longer appropriate. This paper describes the multiple drivers of sales strategy in oncology markets today. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Research Learn how the right chemical inventory strategy helped save a mid-size CDMO millions of dollars while securing a stable supply of products with just-in-time delivery. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Webinar Download this webinar to learn how to avoid pitfalls when characterizing CAR-T cells in your development workflow, how to save time by using one antibody to examine your entire panel of CARs, and more. Sponsored by: Cell Signaling Technology |
Whitepaper Learn more about the current challenges and issues that eClinical technology providers are facing. Sponsored by: YPrime |
| |
|
